Evidence map›Paper›PMID 37786680›Full record

ArticlebioRxiv : the preprint server for biology2024

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib.

Ying Pang, Qi Li, Zach Sergi, Guangyang Yu, Xueyu Sang, Olga Kim, Herui Wang, Alice Ranjan, Mythili Merchant, Belene Oudit and 16 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 1 country.

Ying Pang
Qi Li
Zach Sergi
Guangyang Yu
Xueyu Sang
Olga Kim
Herui Wang
Alice Ranjan
Mythili Merchant
Belene Oudit
Robert W Robey
Ferri Soheilian
Bao Tran
Felipe J Núñez
Meili Zhang
Hua Song
Wei Zhang
Dionne Davis
Mark R Gilbert
Michael M Gottesman
Zhenggang Liu
Javed Khan
Craig J Thomas
Maria G Castro
Taranjit S Gujral
Jing Wu
National Institutes of Health · USUniversity of Michigan · USLeidos (United States) · USNational Cancer Institute · US

Funding

Pre-clinical Translational Research FacilityZICBC011641 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WU, JING · 2015 to 2025
$22.2M
Mechanisms of non-classical multidrug resistance in cancerZIABC010830 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GOTTESMAN, MICHAEL · 2009 to 2025
$19.6M
Discovering novel therapies for glioma patientsZIABC011840 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WU, JING · 2018 to 2025
$4.6M
6 · The paper itself

Abstract

Isocitrate dehydrogenase (IDH)-mutant gliomas have distinctive metabolic and biological traits that may render them susceptible to targeted treatments. Here, by conducting a high-throughput drug screen, we pinpointed a specific susceptibility of IDH-mutant gliomas to zotiraciclib (ZTR). ZTR exhibited selective growth inhibition across multiple IDH-mutant glioma Highlights: Zotiraciclib (ZTR), a CDK9 inhibitor, hinders IDH-mutant glioma growth

Identifiers

PMID37786680
PMCPMC10541587
OpenAlexW4382866827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.